Update information

June 2026: We updated recommendation 1.1, and sections 2.5 and 2.6, to remove reference to a commercial arrangement and to update the list price for bempedoic acid and bempedoic acid–ezetimibe.

Minor changes since publication

September 2021: We added a clarification to 'Why the committee made these recommendations' to say that NICE was not able to evaluate bempedoic acid plus ezetimibe with low intensity statins when higher intensity statins are not tolerated. We also clarified that the cost-effectiveness estimates were for bempedoic acid plus ezetimibe when statins are contraindicated or not tolerated.

ISBN: 978-1-4731-9451-9